Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Accelerated approvals hit the target in precision oncology

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Beaver, J. A. et al. N. Engl. J. Med. 384, e68 (2021).

    Article  CAS  Google Scholar 

  2. US Food and Drug Administration Safety and Innovation Act; Public Law 112-144 (2012)

  3. Kazandjian, D. et al. Clin. Cancer Res. 22, 1307–1312 (2016).

    Article  CAS  Google Scholar 

  4. Howlader, N. et al. N. Engl. J. Med. 383, 640–649 (2020).

    Article  CAS  Google Scholar 

  5. Ramagopalan, S. et al. BMC Med. 19, 209 (2021).

    Article  CAS  Google Scholar 

  6. Singh, H. et al. JAMA Oncol. 7, 829–830 (2021).

    Article  Google Scholar 

  7. Thein, K. Z. et al. Trends Cancer 7, 1074–1088 (2021).

    Article  CAS  Google Scholar 

  8. Richardson, N. C. et al. Lancet Oncol. 23, 563–566 (2022).

    Article  CAS  Google Scholar 

  9. Longo, D. L. N. Engl. J. Med. 371, 2227–2228 (2014).

    Article  Google Scholar 

  10. Beaver, J. A. et al. N. Engl. J. Med. 386, 1297–1301 (2022).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

V.S. is an Andrew Sabin Family Foundation Fellow at The University of Texas MD Anderson Cancer Center, acknowledges support of The Jacquelyn A. Brady Fund, is supported by a US National Institutes of Health (NIH) grant (no. R01CA242845 and R01CA273168). MD Anderson Cancer Center Department of Investigational Cancer Therapeutics is supported by the Cancer Prevention and Research Institute of Texas (no. RP1100584), the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (no. 1U01 CA180964), a NCATS (Center for Clinical and Translational Sciences) grant (no. UL1 TR000371), and the MD Anderson Cancer Center support grant (no. P30 CA016672). The content is solely the responsibility of the authors and does not necessarily represent the official views of the US NIH or FDA.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Vivek Subbiah or Gautam U. Mehta.

Ethics declarations

Competing interests

V.S. reports research funding or grant support for clinical trials from AbbVie, Agensys, Inc., Alfasigma, Altum, Amgen, Bayer, BERG Health, Blueprint Medicines Corporation, Boston Biomedical, Inc., Boston Pharmaceuticals, Celgene Corporation, D3 Bio, Inc., Dragonfly Therapeutics, Inc., Exelixis, Fujifilm, GlaxoSmithKline, Idera Pharmaceuticals, Inc., Incyte Corporation, Inhibrx, Loxo Oncology/ Eli Lilly, MedImmune, MultiVir, Inc., NanoCarrier, Co., National Comprehensive Cancer Network, NCI-CTEP, Novartis, PharmaMar, Pfizer, Relay Therapeutics, Roche/Genentech, Takeda, Turning Point Therapeutics, UT MD Anderson Cancer Center and Vegenics Pty Ltd.; travel support from ASCO, ESMO, Helsinn Healthcare, Incyte Corporation, Novartis and PharmaMar; consultancy or advisory board participation for Helsinn Healthcare, Incyte Corporation, Loxo Oncology/Eli Lilly, MedImmune, Novartis, QED Therapeutics, Relay Therapeutics, Daiichi-Sankyo, and R-Pharm US; and other relationships with Medscape. L.W. receives consulting income from Bayer, Coherus, Curie Therapeutics, Eisai, Exelixis, Lilly and Novartis and has received fees for sitting on a Data Monitoring Committee for PDS Biotechnology. R.K. has received research funding from Biological Dynamics, Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Takeda and TopAlliance; as well as consultant fees, speaker fees or is an advisory board member for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Biological Dynamics, Daiichi Sankyo, Inc., EISAI, EOM Pharmaceuticals, Iylon, Merck, NeoGenomics, Neomed, Pfizer, Prosperdtx, Roche, TD2/Volastra, Turning Point Therapeutics and X-Biotech; has an equity interest in CureMatch Inc., CureMetrix,and IDbyDNA; serves on the Board of CureMatch and CureMetrix, and is a co-founder of CureMatch. All other co-authors have no other conflicts.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Subbiah, V., Wirth, L.J., Kurzrock, R. et al. Accelerated approvals hit the target in precision oncology. Nat Med 28, 1976–1979 (2022). https://doi.org/10.1038/s41591-022-01984-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-022-01984-z

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer